Innovative Cancer TherapyAkari announced preclinical data demonstrating activity of its antibody drug conjugate (ADC) novel payload PH1 in prostate cancer, particularly in the presence of AR-V7, a splice variant of the androgen receptor that is a key driver of progression of metastatic castration resistant prostate cancer (mCRPC).
Potential For Combination TherapiesPH1 demonstrated activity as a single agent as well as a combination with ARPIs, further demonstrating its mechanism of action in blocking the spliceosome and driving direct cytotoxic effects.
Safety And Efficacy AdvantagePH1 has considerable advantages in terms of its safety/toxicity profile, immune-driven bystander effects, and potential for combinations with immune therapies like checkpoints.